EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieKohortenstudieOpen Access · CC BY 4.0

Impact of Early COVID‐19 Antiviral Therapy on the Incidence of Uveitis: A Retrospective Cohort Study Using the TriNetX Database

Hou-Ting Kuo, Alan Y Hsu iD, De-Yi Liu, Bing-Qi Wu iD, James Cheng-Chung Wei iD, Ning-Yi Hsia, Yi-Ching Shao, Chun-Ting Lai, Chun-Chi Chiang, Chun-Ju Lin iD, Huan-Sheng Chen iD, Yu-Hsun Wang und 3 weitere

Immunity, Inflammation and Disease · 2026-05 · 14 (5)

DOI: 10.1002/iid3.70455 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 06.05.2026. Verfasst von Hou-Ting Kuo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, China Medical University Hospital, China Medical University, Taichung, Taiwan. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19, COVID-19 Drug Treatment, Uveitis. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess whether antivirals are associated with a reduced incidence of uveitis following COVID‐19.

Methods

We conducted a multi‐institutional, population‐based retrospective cohort study of adults (≥ 18 years) diagnosed with COVID‐19 between 2022 and 2024. Patients who received antiviral agents (Paxlovid, Molnupiravir, or Remdesivir) within 5 days of diagnosis were matched 1:1 with untreated controls using propensity score matching. Patients with pre‐existing uveitis, early‐onset uveitis within 5 days of the index date, or underlying systemic inflammatory or infectious diseases were excluded. The primary outcome was new‐onset uveitis, with hazard ratios (HRs) calculated across follow‐up intervals.

Results

After matching, 438,455 patients were included in both the antiviral and non‐antiviral groups. Antiviral therapy was associated with a significantly lower risk of uveitis at 3 months (HR = 0.62, 95% CI: 0.45–0.87), 6 months (HR = 0.68, 95% CI: 0.54–0.87), 1 year (HR = 0.76, 95% CI: 0.64–0.91), 3 years (HR = 0.80, 95% CI: 0.70–0.92), and all duration (HR = 0.81, 95% CI: 0.71–0.93). Subgroup analysis revealed consistent benefit across all age groups, with females experiencing greater protection than males. Significant reductions in uveitis risk were observed among patients with diabetes (HR = 0.68, 95% CI: 0.52–0.89), hyperlipidemia (HR = 0.78, 95% CI: 0.65–0.95), and heart failure (HR = 0.52, 95% CI: 0.30–0.90). Among the antivirals, Paxlovid was associated with a significant risk reduction (HR = 0.83, 95% CI: 0.71–0.96), whereas Molnupiravir and Remdesivir showed no statistically significant effect. CEV classification did not show significant improvement. Besides, the risk reduction was evident regardless of prior COVID‐19 vaccination status.

Conclusions

Early antiviral treatment for COVID‐19 such as Paxlovid, is associated with a reduced risk of uveitis. These findings suggest that, in addition to mitigating systemic disease progression, antiviral therapy may confer ocular protective effects, which could be especially meaningful for high‐risk populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCOVID-19COVID-19 Drug TreatmentUveitisAdultAgedFemaleHumansMaleMiddle AgedDatabases, FactualIncidenceRetrospective Studies

Stichwörter der Autor:innen

COVID‐19antiviraluveitis

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Ophthalmology, China Medical University Hospital, China Medical University, Taichung, Taiwan.
  • Department of General Medicine, China Medical University Hospital, Taichung, Taiwan.
  • Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.
  • Department of Nursing, Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
  • School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.

ORCID-Profile: Alan Y Hsu, Bing-Qi Wu, James Cheng-Chung Wei, Chun-Ju Lin, Huan-Sheng Chen, Yi-Yu Tsai

Zitieren

APA

Kuo, H. T., Hsu, A. Y., Liu, D. Y., Wu, B. Q., Wei, J. C., Hsia, N. Y., Shao, Y. C., Lai, C. T., Chiang, C. C., Lin, C. J., Chen, H. S., Wang, Y. H., Tseng, H., Hsu, H. C., & Tsai, Y. Y. (2026). Impact of Early COVID‐19 Antiviral Therapy on the Incidence of Uveitis: A Retrospective Cohort Study Using the TriNetX Database. Immunity, Inflammation and Disease, 14(5). https://doi.org/10.1002/iid3.70455

Vancouver

Kuo HT, Hsu AY, Liu DY, Wu BQ, Wei JC, Hsia NY, et al. Impact of Early COVID‐19 Antiviral Therapy on the Incidence of Uveitis: A Retrospective Cohort Study Using the TriNetX Database. Immunity, Inflammation and Disease. 2026;14(5). doi:10.1002/iid3.70455

BibTeX
@article{Kuo2026,
  author = {Kuo, Hou-Ting and Hsu, Alan Y and Liu, De-Yi and Wu, Bing-Qi and Wei, James Cheng-Chung and Hsia, Ning-Yi and Shao, Yi-Ching and Lai, Chun-Ting and Chiang, Chun-Chi and Lin, Chun-Ju and Chen, Huan-Sheng and Wang, Yu-Hsun and Tseng, Hsin and Hsu, Ho-Che and Tsai, Yi-Yu},
  title = {Impact of Early COVID‐19 Antiviral Therapy on the Incidence of Uveitis: A Retrospective Cohort Study Using the TriNetX Database},
  journal = {Immunity, Inflammation and Disease},
  year = {2026},
  volume = {14},
  number = {5},
  doi = {10.1002/iid3.70455}
}
Kostenlos starten →